

Medicines for Human Life Today and Tomorrow





YUNGIN PHARM



Name	Yungjin Pharm. Co., Ltd.
Foundation	<ul style="list-style-type: none">• 1952 (Public opened in 1973)• 2004 (Merged with KT&G, Korean Tomorrow and Global)
Representatives	Byung-Hwan Ryoo / President, CEO
Location	451-20, Cheonho-3dong, Gangdong-gu, Seoul, Korea
Core Business	<ul style="list-style-type: none">• Manufacturing Pharmaceutical goods (API and Finished Products)• Sales in Domestic and Overseas Markets
Employees	538 (Headquarter : 48, Factory : 198, R&D Lab. : 45, MR : 247)
Key Facilities	Head office (Seoul), 3 Factories (API, Finished Dosage, Drinks) 13 Branches, 1 Central Research Lab. (Synthesis, Formulation)
Annual Sales	KRW 101 Billion (USD 101 Million), as of Dec. 2011



Corporate Profile

Since its establishment in 1952, Yungjin Pharm. Co., Ltd has been enjoying the privilege of playing a major role as a forerunner in the Korean pharmaceutical industry for over half a century. In accordance with our inspiring mission statement, “Relieve the suffering mankind from disease with effective and safe pharmaceutical products on our own” we have been contributing to improve lives of human beings for the better.

In order to establish a solid foundation, Yungjin Pharm. Co., Ltd. joined the KT&G as a member group on March 29, 2004. This merge enables us to reform ourselves as a company of enduring strength with sufficient resources for R&D sector and further development.

Based on our long-term goal, we strive for further growth and expansion. Strong alliance with the worldwide pharmaceutical companies allows us to expand our market into the worldwide and cope with the challenging environment of global pharmaceutical industry.

Through active involvement in R&D activities, quality management and overseas business, we will fulfill the expectations of our customers and shareholders. Our employees dedicate themselves to provide high-quality products and services to our customers.

Message from CEO

I deeply thank you for your interest and encouragement in Yungjin Pharm Co., Ltd.

Yungjin Pharm. is to move forward forever and always ready to imagine a future with passion. It also challenge the impossible dream to come true with its passional fortitude. Our Vision is to establish Yungjin as a leading global pharmaceutical company.

Since its establishment of Yungjin Pharm. in 1952, we have a proud history of contributing to the public health by developing and supplying excellent pharmaceutical products for people who are suffering from many diseases. We, however, went through many adversities and challenges. Yet, Yungjin pharm. now set firm goals.

First, Achieving an outstanding financial outcome
Second, Providing satisfactory welfare to all the staff members
Third, Building a respectable company in the society

With the challenge, passion and creative thinking, Yungjin Pharm. should carry out our duty to the fullest to grow continuously. You should give an attention that Yungjin Pharm. will be transformed as a top and global pharmaceutical company in five years.

Thank you again for your interests in Yungjin Pharm., and please remember that our door is always widely opened to our valued customers.

Sincerely,
CEO Ryoo, Byunghwan



History

Global Biopharmaceutical Company

The vision of Yungjin is to advance into a leading global biopharmaceutical company. We are ambitious to expand our market into the world and broaden the scope of our products, thus, contributing to the public health and well-being of people in the global community.

In tune with the mid to long term master plan, we have designed a leading business portfolio to evolve our organization. We now strive to strengthen our core business throughout the cooperation with our affiliates and development of potential growth. By implementing three core beliefs of our overachieving philosophy of “Righteousness”, “Enlightenment” and “Companionship”, we are committed to serve our customers with the best efforts. For the upcoming years, our employees are ready to maximize their capabilities so that we can develop as a leading global pharmaceutical company.



Total Quality Management

To guarantee the top quality of its pharmaceutical products, Yungjin works to maintain the top quality management system. Our quality assurance department is responsible for maintaining “Total Quality Management” through streamlined arrangement of responsibilities, processes, and resources.

The laboratory of quality control is responsible for developing new methodologies of drug compound and related analytical procedure for better quality. With continuous research and monitoring system, our staffs guarantee the quality of our products.



1952

Establishment manufacturing
(Trading & Distribution)



1962

Commencement of
manufacturing



1972

Growing as a
pharmaceutical leader



1983

Expanding of site and
business areas to worldwide



1989

Completion and expansion
of Namyang GMP plants



1993

Establishment of Iksan
drink factory



2004

Joining as a member of
KT&G group



Present

Global challenges



Plant

Yungjin holds sufficient resources to produce a wide range of products from its three main factory sites and one R&D institute. Since 2005, Jeonju factory has been producing top quality API (Active pharmaceutical ingredients) using innovative production technologies. Namyang formulation factory was established in the late 1980's and it has been supplying various kinds of dosage forms such as injections, tablets, capsules, infusions and more. Since its establishment in 1990, Iksan drink factory has been supplying drinks and ginseng containing tonic. The Iksan drink factory was established in 2000 which has been supplying Pravastatin Sodium by fermentation process.

We have completed the major renovations on the two factory sites, Namyang and Jeonju to comply with new GMP guideline. Dedicated facilities for Cephalosporin and General medicines was established in 2011 on both sites. This will offer promising business and enhanced competitiveness.

Central R&D institute in Suwon focuses on the development of synthetic methods of Active Pharmaceutical Ingredients and pharmaceutical intermediates. In R&D center, Various Key projects are under development of new drug formulation, drug delivery system and optimization of prescription.

>>> KT&G



After successfully completing its privatization in 2002, KT&G has capitalized upon lessons of its experiences to take stronger initiatives to reform and innovate its businesses, thereby effectively executing its business model diversification strategies and achieving solid management performance results. As a consequence, KT&G has grown into a globally competitive company, facilitating enhanced communication among stakeholders and practicing a sustainable growth management.

By applying the three core beliefs of its management philosophy- “Righteousness”, “Enlightenment”, and “companionship” -to every aspect of its business engagement, KT&G has continued to receive commendations and respect for its business transparency and ethics such as corporate governance, ethical and transparent management practices and business innovations, among others. KT&G has also shared created values with its clients, shareholders and constituents, further with the society at large with a greater sense of balance.

While improving superior product quality and manufacturing capabilities by competing with foreign cigarette manufacturers operating their production bases in Korea, KT&G has dominated domestic market over 70% by developing and releasing new products marked by ceaseless technological innovations. KT&G has also successfully developed over 40 export markets including Russia, CIS, Middle East, Central Asia, China and Southeast Asia with its flagship product “Esse” spearheading its campaign.


In order to enhance its corporate value, KT&G will continue to reform and innovate its organization and businesses alike. By further strengthening its core business, developing growth drivers for the next generation, and achieving a better balanced business portfolio, KT&G will take a large step toward building an exceptional global business of far stronger growth potential, profitability, stability and sustainability.

Active Pharmaceutical Ingredient (API)



»» Cephalosporin

1. Cefaclor Monohydrate



Molecular formula: $C_{15}H_{14}ClN_3O_4S \cdot H_2O$ (M.W: 385.83)

CAS Registry number: 70356-03-5


Specification: USP, EP, JP, KP

Description: White to yellowish white crystalline powder

Assay: 960 ~ 1020 $\mu\text{g}/\text{mg}$ (as cefaclor and anhydrous basis)

Packaging: 25 kg, Fiber drum

2. Cefpodoxime Proxetil



Molecular formula: $C_{21}H_{27}N_5O_9S_2$ (M.W: 557.60)

CAS Registry number: 87239-81-4


Specification: JP

Description: White to light brownish white powder

Assay: 706 ~ 774 $\mu\text{g}/\text{mg}$ (as cefpodoxime and anhydrous basis)

Packaging: 20 kg, Fiber drum

3. Cefcapene Pivoxil HCl



Molecular formula: $C_{23}H_{29}N_5O_8S_2 \cdot HCl \cdot H_2O$ (M.W:622.11)

CAS Registry number: 147816-24-8


Specification: JP, KP

Description: White to pale yellowish white crystalline powder

Assay: 722 ~ 764 $\mu\text{g}/\text{mg}$ (as cefcapene and anhydrous basis)

Packaging: 5, 10, 15 kg, Fiber drum

4. Cefamandole Nafate



Molecular formula: $C_{19}H_{17}N_5NaO_6S_2$ (M.W: 512.50)

CAS Registry number: 42540-40-9


Specification: EP, KP, CP

Description: White to almost white crystalline powder

Assay: 93.0 ~ 102.0 % (as cefamandole nafate and anhydrous basis)

Packaging: 5kg, Aluminium can

5. Ceftazidime Pentahydrate



Molecular formula: $C_{22}H_{22}N_6O_7S_2 \cdot 5H_2O$ (M.W: 598.56)

CAS Registry number: 78439-06-2


Specification: JP, KP

Description: White to light yellowish white crystalline powder

Assay: 950 ~ 1020 $\mu\text{g}/\text{mg}$ (as ceftazidime and dried basis)

Packaging: 10 kg, Aluminium can

6. Cefmetazole Sodium



Molecular formula: $C_{15}H_{16}N_7NaO_5S_3$ (M.W: 493.52)

CAS Registry number: 56796-39-5


Specification: JP, KP, CP

Description: White to light yellowish white powder

Assay: 860 ~ 965 $\mu\text{g}/\text{mg}$ (as cefmetazole and anhydrous basis)

Packaging: 10 kg, Aluminium can

7. Cefadroxil Monohydrate



Molecular formula: $C_{16}H_{17}N_3O_5S \cdot H_2O$ (M.W: 381.41)

CAS Registry number: 66592-87-8


Specification: USP, JP, KP

Description: White to light yellow-white powder

Assay: 950 ~ 1020 $\mu\text{g}/\text{mg}$ (as cefadroxil and anhydrous basis)

Packaging: 25 kg, Fiber drum

8. Cefotiam HCl



Molecular formula: $C_{18}H_{23}N_9O_4S_3 \cdot 2HCl$ (M.W: 598.56)

CAS Registry number: 66309-69-1

Specification: JP, KP


Description: White to light yellow crystalline powder

Assay: 810 ~ 890 $\mu\text{g}/\text{mg}$ (as cefotiam and anhydrous basis)

Packaging: 10 kg, Aluminium can

>>> Cephalosporin

9. Cefotiam Hexetil HCl



Molecular formula: $C_{27}H_{37}N_9O_7S_3$ (M.W: 768.76)

CAS Registry number: 95789-30-3


Specification: JP

Description: White to light yellow powder

Assay: 615 ~ 690 $\mu\text{g}/\text{mg}$ (as cefotiam and anhydrous basis)

Packaging: 25kg, Fiber drum

10. Ceftizoxime Sodium



Molecular formula: $C_{13}H_{12}N_5NaO_5S_2$ (M.W: 405.38)

CAS Registry number: 68401-82-1


Specification: JP, KP, CP

Description: White to light yellow crystalline powder

Assay: Not less than 900 $\mu\text{g}/\text{mg}$ (as ceftizoxime and anhydrous basis)

Packaging: 10 kg, Aluminium can

11. Cefatrizine Propylene Glycolate



Molecular formula: $C_{18}H_{18}N_6O_5S_2 \cdot C_3H_8O_2$ (M.W: 538.60)

CAS Registry number: 64217-62-5


Specification: JP, KP

Description: White to yellowish white powder

Assay: 758 ~ 876 $\mu\text{g}/\text{mg}$ (as cefatrizine and anhydrous basis)

Packaging: 25 kg, Fiber drum

12. Flomoxef Sodium



Molecular formula: $C_{15}H_{17}F_2NaO_7S_2$ (M.W: 517.45)

CAS Registry number: 99665-00-6


Specification: JP

Description: White to light yellowish white powder or mass

Assay: 870~ 985 $\mu\text{g}/\text{mg}$ (as anhydrous basis)

Packaging: 10kg, Aluminium can

13. Latamoxef Sodium



Molecular formula: C₂₀H₁₈N₆Na₂O₉S (M.W: 564.44)

CAS Registry number: 64952-97-2


Specification: JP, CP

Description: White to light yellowish white, powder or masses

Assay: 830 ~ 940 μg/mg (as anhydrous basis)

Packaging: 10kg, Aluminium can

14. Cefozopran HCl



Molecular formula: C₁₉H₁₇N₉O₅S₂ · HCl: 551.99

CAS Registry number: 113359-04-09


Specification: JP

Description: White to pale yellow crystals or crystalline powder

Assay: 860 ~ 960 μg/mg (as anhydrous basis)

Packaging: 10kg, Aluminium can

15. Cefditoren Pivoxil



Molecular formula: C₁₉H₁₈N₆O₅S₃

CAS Registry number: 104145-95-1

Specification: EP, JP


Description: Light yellowish white to light yellow crystalline powder

Assay: 770 ~ 820 μg/mg (as cefotiam and anhydrous basis)

Packaging: 25kg, Fiber drum

»» Under Development

1. Ceftaroline Fosamil




Molecular formula: C₂₄H₂₅N₈O₁₀PS₄

CAS Registry number: 400827-46-5

Specification: In-house

1. Famciclovir



Molecular formula: C₁₄H₁₉N₅O₄ (M.W: 321.33)

CAS Registry number: 104227-87-4


Specification: USP, EP

Description: White to light yellow powder

Assay: 98.0 ~ 102.0 % (as anhydrous basis)

Packaging: 25 kg, Fiber drum

2. Candesartan Cilexetil



Molecular formula: C₃₃H₃₄N₆O₆ (M.W: 610.67)

CAS Registry number: 145040-37-5


Specification: JP

Description: White crystalline powder

Assay: 99.0 ~ 101.0 % (as anhydrous basis)

Packaging: 5, 10, 25 kg, Fiber drum

3. Olmesartan Medoxomil



Molecular formula: C₂₉H₃₀N₆O₆ (M.W: 558.58)

CAS Registry number: 144689-63-4


Specification: EP

Description: White to light yellowish powder

Assay: 99.0 ~ 101.0 % (as anhydrous and corrected on the amount of residual solvent)

Packaging: 5, 10, 25 kg, Fiber drum

4. Losartan Potassium



Molecular formula: C₂₂H₂₂ClKN₆O (M.W: 461.01)

CAS Registry number: 124750-99-8


Specification: USP, KP

Description: White crystalline powder

Assay: 98.5 ~ 101.0 % (as losartan and anhydrous basis)

Packaging: 25 kg, Fiber drum

5. Rosuvastatin Calcium



Molecular formula: $(C_{22}H_{27}FN_3O_6S)_2Ca$ (M.W: 1001.14)

CAS Registry number: 147098-20-2


Specification: USP, EP, JP

Description: White amorphous powder

Assay: 97.0 ~ 103.0 % (as anhydrous and corrected on the amount of residual solvent)

Packaging: 5, 10, 25 kg, Fiber drum

6. Benidipine HCl



Molecular formula: $C_{28}H_{31}N_3O_6 \cdot HCl$ (M.W: 542.02)

CAS Registry number: 91599-74-5


Specification: JP

Description: Yellow crystalline powder

Assay: 99.0 ~ 101.0 % (as dried basis)

Packaging: 25 kg, Fiber drum

7. Meloxicam



Molecular formula: $C_{14}H_{13}N_3O_4S_2$ (M.W: 351.41)

CAS Registry number: 71125-38-7


Specification: BP, KP

Description: Light yellow powder

Assay: 99.0 ~ 100.5 % (as dried basis)

Packaging: 5, 10, 25 kg, Fiber drum

8. Pantoprazole Sodium



Molecular formula: $C_{16}H_{14}F_2N_3NaO_4S \cdot 1.5 H_2O$ (M.W: 432.38)

CAS Registry number: 138786-67-1

Specification: USP, EP, JP


Description: White to light yellowish white powder

Assay: 98.0 ~ 102.0 % (as anhydrous)

Packaging: 25 kg, Fiber drum

»» General

9. Piprinhydrate



Molecular formula: C₂₆H₃₀ClN₅O₃ (M.W: 496.00)

CAS Registry number: 606-90-6


Specification: KP, JP

Description: White crystalline powder

Assay: Not less than 98.0 % (as dried basis)

Packaging: 25 kg, Fiber drum

10. Propacetamol HCl



Molecular formula: C₁₄H₂₁ClN₂O₃ (M.W: 300.79)

CAS Registry number: 66532-86-3

Specification: EP


Description: White to light yellowish white crystalline powder

Assay: 98.0 ~ 102 % (as dried basis)

Packaging: 10 kg, Aluminium can

»» Under Development

1. Entacapone




Molecular formula: C₁₄H₁₅N₃O₅

CAS Registry number: 130929-57-6

Specification: USP

2. Pitavastatin Calcium



Molecular formula: C₅₀H₄₆CaF₂N₂O₈

CAS Registry number: 147526-32-7

Specification: USP, EP, JP

FINISHED PRODUCTS



>>> Antibiotics

I. Cephalosporin

1. Cefmetazole inj. 1.0g



Active ingredient: Cefmetazole Sodium

Characteristics

- (1) Oral 2nd generation cephalosporin antibiotics
- (2) Excellent effect on anaerobic and aerobic microorganisms

Dosage

Adults: 1~4g (potency), in two divided doses. I.V.

Package: 500mg/vial x 10vials, 1g/vial x 10vials, 2g/vial x 10vial

2. Ceftazidime inj. 1.0g, 0.5g



Active ingredient: Ceftazidime Pentahydrate

Characteristics

- (1) 3rd generation cephalosporin antibiotics
- (2) Broad spectrum beta-lactam antibiotics

Dosage

Adults: 0.5~2g, 2~3 times daily, I.V. or I.M.

Children: 30~100mg/kg divided into 2~3 times daily I.V. or I.M.

Package: 500mg/vial x 10vials, 1g/vial x 10vials

3. Cefamandole inj. 1.0g, 0.5g



Active ingredient: Cefamandole Nafate

Characteristics

- (1) 2nd generation cephalosporin antibiotics
- (2) Broad spectrum cephalosporin antibiotics

Dosage

500mg to 1g is given every 4~8 hours, I.V. or I.M.

Package: 500mg/vial x 10vials, 1g/vial x 10vials

4. Cefpirom inj. 1.0g, 0.5g

Cefpirom inj.

Active ingredient: Cefpirom Sulfate

Characteristics

- (1) 4th generation cephalosporin antibiotics
- (2) Broad spectrum beta-lactam antibiotics

Dosage

Adults: 1~2g (potency), in two divided doses, I.V.

Package: 500mg/vial x 10vials, 1g/vial x 10vials

5. Cefotiam inj. 1.0g, 0.5g



Active ingredient: Cefotiam HCl

Characteristics

- (1) 2nd generation cephalosporin antibiotics
- (2) Broad spectrum cephalosporin antibiotics
- (3) Excellent effect on G(-) microorganisms surpassing 3rd generation cephalosporins

Dosage

Adults: 0.5g-2g(potency)/day, in 2~4 divided doses, I.V. or I.M.
 Children: 40~80mg(potency)/kg/day, in 3~4 divided doses, I.V.

Package: 500mg/vial x 10vials, 1g/vial x 10vials

6. Cefpodoxime Proxetil tab. 100mg/ Dry Syrup 50ml (Cepoxetil)



Active ingredient: Cefpodoxime Proxetil

Characteristics

- (1) Oral 3rd generation cephalosporin antibiotics
- (2) Acting as a prodrug

Dosage

Adults: 1 tablet, 2 times daily after meals

Package: 100mg/tab x 30T, 200T, 50ml bottle

7. Cefcapene Pivoxil tab. 75mg, 100mg/ Granule



Active ingredient: Cefcapene Pivoxil HCl monohydrate

Characteristics

- (1) Oral 3rd generation cephalosporin antibiotics
- (2) Broad spectrum of gram-positive and gram-negative bacteria
- (3) Highly stable to most clinically important beta-lactamases
- (4) Pro-drug, having a pivoxil group to improve the absorbing rate in digestive system

Dosage

Adults: 1 tablet, 3 times daily after meals

Package: 100mg/tab x 100T, 200T, 500T

8. Cefprozil tab. 250mg / Syr. 125mg/5mg (Ceropazil tab)



Active ingredient: Cefprozil

Characteristics

- (1) Oral 2nd generation cephalosporin antibiotics
- (2) Interferes with bacterial cell-wall synthesis and division by binding to cell wall

Dosage

6months ~ 12yrs: 15mg/kg/12hours (10days)

Over 13yrs: 500mg once daily or 250mg twice daily


Package: 250mg/tab x 30T, 100T

125mg/5ml x 60ml bottle

>>> Antibiotics

I. Cephalosporin

9. Cefaclor cap. 250mg / Syr. 200ml



Active ingredient: Cefaclor Monohydrate

Characteristics

- (1) 2nd generation oral cephalosporin antibiotic
- (2) Excellent effect on respiratory infection and urinary tract infections

Dosage

Adults: One cap. 3 times daily

Children: 20mg/kg as divided dose 3 times daily

Package: 250mg/cap. x 100 caps. 125mg/5ml x 1 bottle

II. Carbapenem

1. Imipenem-Cilastatin inj. 0.5g



Active ingredient: Imipenem Monohydrate, Cilastatin Sodium

Characteristics

- (1) Beta-lactam antibiotics
- (2) Broad spectrum antibiotics for treatment of serious infections

Dosage

500 ~ 1000mg (potency)/day over 30 minutes for 2~3 times injection, I.V.

Package: 500mg/vial x 10vials

2. Meropenem inj. 0.5g, 1g



Active ingredient: Meropenem

Characteristics

- (1) Beta-lactam antibiotics
- (2) Ultra-broad spectrum to treat a wide variety of infections

Dosage

Adult: 1g, three times daily

Children: 20-40mg/kg, three times daily

Package: 500mg/vial x 10vials, 1g/vial x 10vials

I. Antipyretic Analgesics & Anti-inflammatory

1. Acetaminophen & Tramadol tab. 325mg(Yungtracet)



Active ingredient: Acetaminophen 325mg + Tramadol 37.5mg

Indications: Moderate, acute pain

Characteristics

Short-term relief of moderately-severe, acute pain

Dosage

2 tablets every 4-6 hours as required (no more than 8 tabs daily)

Package: 325mg/37.5mg tab x 30T, 100T

2. Dexibuprofen syr. 1.2g (Dexiprufen syr.)



Active ingredient: Dexibuprofen

Indications: Pain and inflammation associated with osteoarthritis, musculoskeletal disorders, dysmenorrhoea and dental pain.

Characteristics

Non-steroidal anti-inflammatory drug

Dosage

Children: 5~7mg(potency)/kg (not more than 28mg/kg daily)

Package: 500ml / bottle

3. Meloxicam tab. 7.5mg (Melbrex)



Active ingredient: Meloxicam

Indications: Osteoarthritis, Rheumatoid Arthritis

Characteristics

(1) Nonsteroidal anti-inflammatory drug with analgesic and fever reducing effects

(2) Low side effects for gastrointestinal tract and cardiovascular system

Dosage

1 tab. once daily

Package: 7.5mg/tab x 30T, 300T

>>> General

II . Antiepileptic drug

1. Pregabalin 75mg, 150mg (Rikalin Cap.)



Active ingredient: Pregabalin

Indications: Epilepsy, neuropathic pain, general anxiety disorder

Characteristics

Used alongside other medicines in the treatment of focal seizures

Dosage

Varies from one person to another. (Doctor's instruction)

Package: 75mg/cap x 30 caps, 150mg/cap

III . Blood circulation

1. Limaprost alfadex 5ug (Opast tab)



Active ingredient: Limaprost alfadex

Indications: Ischemic symptoms such as ulcer, pain and feeling coldness, Lumbar spinal canal stenosis

Characteristics

(1) Alprostadil (prostaglandin E1) analogue

(2) A vasodilator that increases blood flow and inhibits platelet aggregation

Dosage

(1) For ischemic symptoms: 2 tablets three times daily

(2) For lumbar spinal canal stenosis: 1 tablet three times daily

Package: 5ug/cap x 84T

2. Ginkgo biloba extracts tab. 40mg/soft capsule 120mg (Ginkapran)



Active ingredient: Ginkgo biloba extracts

Indications: Promoting blood circulation

Characteristics

High concentrated Ginkgo biloba extracts

Dosage

1 capsule twice daily

Package: 40mg/tab x 100T

120mg/cap x 120 caps x 2

IV. Benign prostatic hyperplasia

1. Tamsulosin SR tab. 0.2mg (Tamlosin SR)



Active ingredient: Tamsulosin HCl

Indications: Benign prostatic hyperplasia

Characteristics

(1) The first subtype-selective ($[\alpha]1A$) $[\alpha]1$ adrenoceptor antagonist

(2) With specificity for prostatic $[\alpha]1$ adrenoceptors

Dosage

1 tablet once daily (adjust the dosage depending on age)

Package: 0.2mg/tab x 100T

V. Cardiovascular (CV)

1. Benidipine tab. 2mg, 4mg, 6mg, 8mg (Codipine)



Active ingredient: Benidipine HCl

Indications: Hypertension, angina

Characteristics

Calcium channel blocker for the treatment of hypertension

Dosage

Hypertension: 2 ~ 4mg once daily after breakfast

Angina: 4mg twice daily after breakfast and dinner

The dosage can be adjusted depending on age and severity

Package: 2mg/tab x 30T, 100T 4mg/tab x 30T, 300T
6mg/tab x 30T, 300T 8mg/tab x 30T, 300T

2. Candesartan Cilexetil tab. 8mg, 16mg Candesartan Cilexetil + HCT 16mg/12.5mg (Cansartan, Cansartan Plus)



Active ingredient: Losartan potassium 50mg, Hydrochlorothiazide

Indications: Hypertension

Characteristics

Angiotensin II receptor antagonist

Dosage

1 tab once daily

Package: 50mg/12.5mg tab (Lozarkan plus) x 30T, 100T

100mg/12.5mg tab (Lozarkan Plus Pro) x 30T, 100T

V. Cardiovascular (CV)

3. Losartan Potassium 50mg, 100mg + Hydrochlorothiazide 12.5mg (Lozarkan Plus tab & Lozarkan Plus Pro tab)



Active ingredient: Losartan potassium 50mg, Hydrochlorothiazide

Indications: Hypertension

Characteristics

Angiotensin II receptor antagonist

Dosage

1 tab once daily

Package: 50mg/12.5mg tab (Lozarkan plus) x 30T, 100T

100mg/12.5mg tab (Lozarkan Plus Pro) x 30T, 100T

4. Pravastatin Sodium tab. 5mg, 10mg, 20mg, 40mg (Prastan)



Active ingredient: Pravastatin Sodium

Indications: High cholesterol

Characteristics

A member of the drug class of statins

Dosage

1 tab once daily

Package: 5mg tab x 30T, 100T

10mg tab x 30T, 100T

20mg tab x 100T, 300T

40mg tab x 100T, 300T

5. Rosuvastatin tab. 5mg, 10mg, 20mg

Rosuvastatin tab.

Active ingredient: Rosuvastatin Calcium

Indications: Primary hypercholesterolemia (Type II a and b), mixed dyslipidemia, elevated serum triglycerides, and homozygous low-density lipoprotein receptor disorder.

Characteristics

A member of the drug class of statins

Dosage

1 tablet once daily

Package: 5mg, 10mg, 20mg tab. x 28T

6. Pitavastatin tab. 2mg

Pitavastatin tab

Active ingredient: Pitavastatin

Indications: Hypercholesterolaemia

Characteristics

A member of the drug class of statins

Dosage

1 tablet once daily

Package: 2mg/tab

7. Nebivolol HCl 5mg (Nebiolet tab)



Active ingredient: Nebivolol HCL

Indications: Hypertension

Characteristics

β1 receptor blocker with high selectivity

Dosage

Hypertension: 1 tab. daily

Renal failure: 0.5 once daily increased to 5mg as required

Over 65: 0.5 once daily, increased to 5mg as required

Chronic renal failure: 0.25 tab daily, increased to 2.5, 5 mg, no more than 10mg

Package: 5mg/tab x 30T, 100T

VI. Central Nervous System (CNS)

1. Donepezil tab. 5mg, 10mg (Hicept tab)



Active ingredient: Donepezil HCl

Indications: Alzheimer's disease, vascular dementia

Characteristics

(1) Acetylcholinesterase inhibitor

(2) Used in all stages of Alzheimer's disease

Dosage

5mg once daily at bedtime, can be increased after 4-6 weeks

Package: 5mg/tab x 30T

10mg/tab x 30T

2. Escitalopram tab. 10mg (Citalo tab)



Active ingredient: Escitalopram oxalate 12.77mg

Indications: Depression

Characteristics

(1) SSRI (Selective serotonin reuptake inhibitor)

(2) Dual action to serotonin transporter (binds to both primary site and allosteric site of 5-HT receptor)

Dosage

1 tab once daily

Package: 10mg/tab x 30T, 100T

20mg/tab x 30T, 100T

VI. Central Nervous System (CNS)

3. Memantine HCl tab. 10mg (Neuro-K)



Active ingredient: Memantine HCl 10mg

Indications: Severe Alzheimer's disease

Characteristics

- (1) NMDA receptor antagonist
- (2) Prevents damages of nerve cells

Dosage

Adult: Start with 5mg daily, increase up to 20mg over 3 weeks

Elderly: 1 tab twice daily

Package: 10mg/tab 30T, 100T

4. Naltrexone HCl tab. 50mg (Naltrexin tab)



Active ingredient: Naltrexone HCl

Indications : Naltrexin is a narcotic antagonist used to treat alcoholics. Naltrexin can be used to treat other conditions such as Crohn's disease or self-injurious behaviors according to your doctors prescription

Characteristics

- (1) Compliance - 1 dose in a day
- (2) No hepatotoxicity
- (3) High efficacy against alcoholics as opioid receptor

Dosage

1 tab. once daily

Package: 50mg/tab x 30T, 100T

5. Venlafaxine HCl 37.5mg, 75mg (Venfaxine SR cap.)



Active ingredient: Venlafaxine HCl

Indications: Depression, social phobia

Characteristics

- (1) Selective Serotonin- and Norepinephrine-reuptake Inhibitors
- (2) Management of major depressive disorder

Dosage

recommended dose: 75mg once daily, 37.5mg twice daily

Package: 37.5mg/tab x 30T, 100T

75mg/cap. x 30T, 100T

6. Pramipexole tab. 0.125mg, 0.25mg, 0.5mg, 1 mg

Pramipexole tab.

Active ingredient: Pramipexole

Indications: Parkinson's disease

Characteristics

Non-ergoline dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes

Dosage

Adjusted by doctors

<p>1. Zolpidem 10mg</p>	<p>Indications: Insomnia, brain disorder Characteristics (1) Short-acting nonbenzodiazepine hypnotic of the imidazopyridine class (2) Works quickly (usually within 15 minutes) Dosage: As directed by doctors</p>
<p>2. Lafutidine 10mg</p>	<p>Indications: Ulcer (antacid) Characteristics H₂ receptor antagonist Dosage: 10mg twice daily</p>
<p>3. Flomoxef inj. 500mg</p>	<p>Indications: Bacterial infections Characteristics Broad spectrum 3rd generation cephalosporin Dosage: 1~2g in 2 divided doses intravenously</p>
<p>4. Latamoxef inj.</p>	<p>Indications: Bacterial infections Characteristics Broad spectrum beta-lactam antibiotic Dosage: 1~2g in 2 divided doses intravenously or intramuscularly</p>
<p>5. Moxifloxacin tab/inj</p>	<p>Indications: Bacterial infections Characteristics 4th generation synthetic fluoroquinolone antibacterial agent Dosage: 400mg once daily</p>
<p>6. Olmesartan tab. 5mg, 20mg, 40mg Olmesartan Plus 20mg/12.5mg</p>	<p>Indications: Hypertension Characteristics Antihypertensive agent, Angiotensin II type 1-receptor antagonist Dosage: 1 tab once daily</p>
<p>7. Acetaminophen & Tramadol SR</p>	<p>Indications: Moderate, acute pain Characteristics 12 hours relief of moderately-severe, acute pain Dosage: 1-2 tablets every 12 hours as required (no more than 4 tabs daily)</p>
<p>8. Pregabalin SR</p>	<p>Indications: Neuropathic pain, partial seizures, anxiety disorders Characteristics (1) Anticonvulsant drug (2) More potent successor to gabapentin Dosage: As directed by doctors</p>
<p>9. Limaprost SR</p>	<p>Indications: Ischemic symptoms such as ulcer, pain and feeling coldness, Lumbar spinal canal stenosis Characteristics (1) Alprostadil (prostaglandin E1) analogue (2) A vasodilator that increases blood flow and inhibits platelet aggregation</p>

YUNGJIN PHARM



451-20 Cheonho-3dong, Gangdong-gu, Seoul, Korea
Tel: +82-2-2041-8270~9 Fax: +82-2-463-9544
E-mail: yjpkj@yungjin.co.kr
www.yungjin.co.kr